Respective prevalence of high‐risk HPVgenotypes in cervical neoplasia in Senegal
Autor: | Oumy Diop‐Diongue, Madeleine Mbow, Nafissatou Ndiaye Ba, Aboubacry Dramé, Mba Elhadji Bambo Diakhaby, B. Dembele, Xavier Sastre-Garau, Gisèle Woto-Gaye, Mamadou Diop, Coumba Toure Kane, Halimatou Diop-Ndiaye |
---|---|
Rok vydání: | 2021 |
Předmět: |
Adult
medicine.medical_specialty Genotype Uterine Cervical Neoplasms Gastroenterology 03 medical and health sciences 0302 clinical medicine Virology Internal medicine Prevalence medicine Humans Papillomavirus Vaccines 030212 general & internal medicine Papillomaviridae Genotyping Cervical cancer Intraepithelial neoplasia business.industry Viral Epidemiology Incidence (epidemiology) Papillomavirus Infections virus diseases Cancer Middle Aged Uterine Cervical Dysplasia medicine.disease Senegal Infectious Diseases High risk hpv Female 030211 gastroenterology & hepatology business |
Zdroj: | Journal of Medical Virology. 93:5110-5117 |
ISSN: | 1096-9071 0146-6615 |
Popis: | Objectives In the perspective of prophylactic vaccination against high-risk human papillomavirus (HPV), we analyzed the viral epidemiology of cervical neoplasia in Senegal. Methods All patients were treated at the Institut Joliot Curie du Cancer in Dakar. HPV genotypes were characterized using a Real-time PCR-based approach and sequencing. Results Histologically, there were 224 invasive carcinomas, 17 high-grade intraepithelial neoplasia (CIN), and 5 undetermined histologies. Molecular analysis was conclusive in 241 cases. HPV DNA was found in 207/241 (85.9%) cases while 34/241 (14.1%) remained HPV negative. There was one single genotype in 127/207 (61.4%) cases and several in 80/207 (38.6%) corresponding to 308 genotypes identified. Viral genotyping found HPV16 in 175 (56.8%) cases, HPV18 in 45 (14.6%), HPV45 in 40 (13.0%), HPV58 in 35 (11.4%), HPV33 in 6 (2.0%), HPV35 in 3 (1.0%), HPV31 in 2 (0.6%), HPV39 and HPV56 in one (0.3% each). Conclusion Our analysis showed that 98.4% of the HPV-positive cases were associated with viral genotypes covered by the 9-valent HPV vaccine. However, 14.1% cases remained HPV negative. Therefore, prophylactic vaccination using 9-valent vaccine should dramatically reduce the incidence of HPV-associated neoplasia but the detection and treatment of CIN remains necessary for the optimal prevention of cervical cancer. This article is protected by copyright. All rights reserved. |
Databáze: | OpenAIRE |
Externí odkaz: |